The limiting factor for radiation (RT) dose-escalation is normal tissue toxicity. In dose-escalation studies, it is important to determine the factors associated with toxicity and the length of follow-up period after which a particular RT dose is considered safe.
Introduction
Conformal radiotherapy (CRT) is an advanced technique of radiation therapy (RT) that accurately conforms the RT dose to the planned target volume, minimizes the risk of missing part of the target, and decreases the volume of unnecessarily treated normal surrounding tissues.
In prostate cancer (PC) patients, CRT has potential for tumor dose escalation to levels higher than those ever feasible with traditional RT, which should result in higher probability of tumor control without increasing the increasing the probability of radiation complications. 1 -3 Short-term results indicate advantages of RT dose escalation in prostate cancer. 4, 5 However, whether long-term toxicity rates will be acceptable with dose escalation remains to be seen because of the relatively short median follow-up time of PC patients treated with high doses of RT in the published dose-escalation studies. 2 -5 By studying the trends and fluctuation of radiation-induced side effects with time after conventional doses of conformal radiotherapy and determining the factors that influence the genitourinary (GU) and gastrointestinal (GI) toxicity from available data, one may be able to predict the length of time needed to observe patients in current experimental dose escalation studies prior to adopting such doses in general practice. Our current study is a step in that direction.
Previous reports have often used 'survival analysis' methods to analyze RT toxicity data. 6, 7 This type of analysis is appropriate for data analyses in which the outcome variable is 'time to event'. When an event occurs (death, relapse, etc) the patient is taken out of the 'population at risk' and patients who are lost for follow-up, withdrawn from the study, or have no event at the end of the study are 'censored'. 8 When such analysis is applied to assess toxicity after RT, patients who report an event (ie toxicity) at any given time-point are not included in subsequent analysis. In other words, the first occurrence of each level of toxicity is given precedence.
However, many patients do experience a certain level of toxicity which improves subsequently, while others would only experience toxicity at later dates, therefore such method of analysis might not be ideal for this type of study (unlike for death or disease-free events where survival analyses are the optimal methods). Most patients who receive radiotherapy for prostate cancer experience some type of toxicity at least once in the first 2 y after the treatment. Thus, using survival-type analysis can inadvertently hide information during subsequent years of follow-up. For these reasons we developed an alternative model to report radiation-induced side effects using logistic regression analysis.
Materials and methods
At the University of Chicago Center for Radiation Therapy (UCCRT), conformal radiation therapy has been utilized in the treatment of prostate cancer since 1988. Our conformal radiation therapy techniques have been detailed in earlier publications. 9, 10 The treatment technique was consistent, as over 90% of our patients received radiotherapy using a four-field technique (anterior/posterior and two lateral portals).
Patient population
Four-hundred and forty-nine patients were included in this analysis with a median follow-up of 27 months (range 0.5 -94 months). The median number of follow-up visits per patient was 6 (range 1 -25). The median interval between follow-up visits was 4 months (range 1 -46 months); in 75% of patients, the intervals between follow-ups were 3 -6 months. Four-hundred and eight patients received a fraction size of 1.9 -2.1 Gy; and 41 patients between 1.7 and 1.9 Gy. The total dose was 60 -67 Gy in 153 patients, 67 -69 Gy in 189 patients. and 69 -74 Gy in 107 patients. The percentage of patients receiving 66, 68 and 70 Gy was 25, 39 and 22%, respectively; for simplicity, patients who received 60 -67 Gy were considered to be in dose level 1 ('66 Gy'): 67 -69 Gy at dose Toxicity after conformal radiotherapy I Abdalla et al level 2 (68 Gy): 69 -74 Gy at dose level 3 ('70 Gy'): overall only 14% received doses other than specified doses of 66, 68 or 70 Gy. The median duration to deliver the treatment was 48 days (range 34 -59 days). The median PSA for our cohort was 12 ng/ml (range 0.4 -420). In 330 patients the prostate volume was available with a median of 73 cm 3 (range 13.2 -131.1 cm 3 ). Our patient cohorts were treated in our two facilities, hospital A (182 patients) and B (267 patients), respectively; these patients were evaluated and treated by our faculty members using similar staging criteria and treatment policies. One-hundred and fourteen patients had stage T1 disease, 246 stage T2 disease and 89 T3 -T4 disease. Ninety-one patients had grade 1 (Gleason score 2 -4), 289 grade 2 (Gleason score 5 -7) and 69 grade 3 (Gleason score 8 -10) tumors. Two-hundred and twentyfive patients were African-American and 224 were white. There were a total of 2724 follow-ups documenting GU toxicity and 2715 follow-ups indicating GI toxicity. The number of follow-ups in the first, second, third, fourth, fifth and after 5 y were 872, 792, 510, 285, 157 and 108 for GU toxicity and 871, 787, 509, 284, 156 and 108 for GI toxicity.
Statistical methods
Separate analyses were carried out for GU and GI toxicities. RTOG late normal tissue toxicity scales were used. All responses for all patients were analyzed. There were only 23 instances of grade 3 toxicity and no instances of grade 4 or 5. As a consequence, we grouped the toxicity levels in two categories and analyzed the binary response. Two groupings of the responses were considered: (a) type 1 grouping -any toxicity (grades 1 -3) vs no toxicity (grade 0); (b) type 2 grouping -high toxicity (grades 2 -3) vs low or no toxicity (grades 1 or 0). Figures 1 and 2 describe the proportion of toxicity events in the data within follow-up time intervals.
The grouped data was analyzed using logistic regression, the standard statistical tool for binary data. (In logistic regression the proportion of toxicity events P is postulated to depend linearly on the covariates through the log-odds ratio, log(P/(1 7 P)).) The covariates included are: patient age, stage and grade of tumor, race, the treatment facility, RT dose, faction size, total duration of treatment, gross tumor volume (GTV) and pre-treatment prostate-specific antigen (PSA). Interaction between these variables and the time of follow-up was also considered.
The purpose of the analysis is three-fold: (1) to study the evolution of the toxicity with the follow-up time, for the entire patient population or for subgroups of patients; (2) to detect patient-specific characteristics (eg radiation dose) that may influence the chronic toxicity; and (3) to evaluate the risks of toxicity after a certain follow-up time for a group of patients.
Our preliminary analysis (by semiparametric additive logistic regression) shows an initial rapid decline in the risk of toxicity following treatment, followed by an increase or stabilization of the toxicity with time of follow-up; the two periods are separated by a 'breakpoint' that differs for GU and GI toxicity. We found the breakpoints to be 2 y (any toxicity) and 1 y (high toxicity) for GU, and 9 months (any toxicity, high toxicity) for GI. Subsequently, a logistic regression was fitted separately for the time interval before, and after the break-up point respectively. We performed a 'univariate' analysis, including only one covariate at a time, and a multivariate analysis. For each model the influence of the covariate on time was modeled in one of three possible 
Results
We observed no grade 4 or 5 toxicities and only 23 instances (5%) of grade 3 toxicity in 20 patients (three patients experience grade 3 GI and GU toxicity). Figures 1  and 2 describe the proportion of toxicity events in the data within follow-up time intervals. Of the five patients with grade 3 GI symptoms, four reported improvement in there symptoms while only 10 out of 18 patients with grade 3 GU symptoms reported improvement. The initial analysis (by semiparametric additive logistic regression) shows an initial rapid decline in the risk of toxicity following treatment, followed by an increase or stabilization of the toxicity with time of follow-up; the two periods are separated by a 'break-point' that differs for GU and GI toxicity. The breakpoints between the two periods were 2 y (any toxicity) and one year (high toxicity) for GU and 9 months (any toxicity, high toxicity) for GI. Figure 1 shows the percentage of patients experiencing toxicity in different follow-up time-intervals after completion of radiation therapy. On univariate analyses result, during the initial 2 y, stage (P < 0.01), race (P < 0.001) and hospital (P < 0.01) where the treatment was administered were important in determining the probability of developing any toxicity. However, in hospital A all patients were white, thus confounding the hospital effect. After the second year, age (P < 0.01), dose (P ¼ 0.04) and tumor grade (P ¼ 0.01) were significant. Older patients, patients with higher grade of tumors, and those who received higher doses encountered a higher percentage of toxicity. The RT dose effect is shown in Figures 4 and 5 . For grades 2 -3 toxicities, duration of treatment (P ¼ 0.01), hospital of treatment (P < 0.01), and race (P < 0.01) were significant before 1 y, and dose (P ¼ 0.06), duration of treatment (P < 0.001), grade (P ¼ 0.08), hospital (P ¼ 0.002) and race (P < 0.001) were significant after the first year.
Genitourinary toxicity
Results of multivariate analyses are shown in Tables 1  and 2 . When analyzed for grades (0 and 1) vs (2 and 3) toxicities, race, dose and duration of treatment were important (Tables 1 and 2 ). The chances of grade 2 or 3 toxicities at the 'breakpoint' (1 y) were 3%. In the second period of toxicity evolution, dose, grade, race, stage and duration of treatment were important for grade 2 and 3 toxicities. The likelihood of developing toxicity for an 'average' patient was 2% at the end of 5 y. When comparing no toxicity vs grade 1 -3 toxicities, GTV, dose, duration of treatment, race and age emerged as important factors in determining the toxicity. There was a 22% Toxicity after conformal radiotherapy I Abdalla et al chance of toxicity shortly after completion of radiation therapy vs 7% toxicity at 2 years for an 'average' patient. Between 2 and 5 y, only age and dose retained their significance; tumor grade and pre-treatment PSA became important factors in the second period of toxicity evolution. Figure 2 shows the percentage of our patients who experienced any toxicity at different follow-up times. On univariate analyses, up to 9 months, only stage had an influence on the development of toxicity with stage T2 patients experiencing less toxicity than stage T1 or T3 patients (P < 0.001). After 9 months, dose (P < 0.001), fraction size (P < 0.01), grade (P ¼ 0.02), stage, age (P < 0.001), GTV (P < 0.01), hospital (P < 0.01) and race (P < 0.01) were significant. The higher the dose, the higher the number of complications ( Figure 5 ). Patients who received 2 Gy or more per fraction had a higher percentage of toxicities than those who received less than 2 Gy per fraction. Patients with higher stage or grade tumors had higher chances of developing toxicities. Older men experienced more toxicities than younger men. The Toxicity after conformal radiotherapy I Abdalla et al higher the GTV, higher were the toxicities. AfricanAmericans experienced fewer toxicities than whitesmen; however, all African-Americans were seen in hospital A. Radiation dose (P < 0.001), tumor grade (P ¼ 0.01), GTV (P < 0.01) and hospital (P ¼ 0.02) were significant up to 9 months after completion of radiation therapy. Dose (P < 0.01) and tumor grade (P ¼ 0.02) retained their significance after 9 months; however, GTV and hospital lost their significance; stage (P ¼ 0.02) and pre-treatment PSA (P ¼ 0.03), which were not associated with GI toxicities up to 9 months, became important after 9 months. The higher the dose, the greater were the toxicities. The higher the stage, tumor grade, GTV or PSA level the higher the toxicities. Hospital B had lower toxicities than hospital A.
Gastrointestinal toxicity
Multivariate results for GI toxicities arc shown in Tables 3 and 4 . For any toxicity, tumor grade and stage were important. The likelihood of an 'average' patient having any toxicity at 9 months was 7%. For the second period of toxicity evolution, stage, age, GTV, dose and race were important.
Discussion
Our observations can be summarized as follows: (a) GU and CI toxicities have different rates of occurrence and evolutions; (b) evolution of low (grade 1) and intermediate grade (grades 2 and 3) toxicities are similar in general; no high-grade toxicities were observed in our patients population; (c) in general, a decline followed by a relative stabilization occurred; (d) age, dose, fraction size, duration of treatment and hospital of treatment emerge as important factors in the probability of developing toxicity; (e) although race also appears important, our data should be interpreted cautiously since hospital A had an all white population and all of our African-American patients were seen in hospital B.
Our findings have important implications for the current ongoing dose-escalation studies and acceptance of such dose escalation in standard practice. A long-term follow-up is necessary before conclusions can be drawn regarding the safety of high doses of radiation therapy using conformal techniques. Since our dose range was relatively narrow (between 66 and 70 Gy in the majority of our patients) the influence of dose on toxicities becomes even more important; it is possible that the steep part of dose -response curve may not be too far higher than 70 Gy and one has to be cautious in escalating dose without getting sufficient time for follow-up between different levels of dose escalations. 11 It is important to note that our doses were all tumor minimum doses; the isocenter dose is generally 3 -5% higher than our prescribed doses, so the isocenter doses are about 68 -69, 70 -71.5 and 72 -73.5 Gy for our prescribed doses of 66, 68 and 70 Gy, respectively.
Given the influence of fraction size in our data, 1.8 -1.9 Gy per fraction may be preferable to avoid long-term toxicities, especially with dose escalation. However, the influence of fraction size on tumor control probabilities in prostate cancer is not known and has to be carefully considered before 1.8 -1.9 Gy is accepted as 'standard' in general clinical practice.
The effect of GTV seen in our data leads one to recommend neoadjuvant hormonal therapy to decrease the prostate volume prior to administration of radiation therapy. Other reports have suggested a significant decrease in the bladder and rectal volume in the high dose region with the use of neoadjuvant hormonal therapy. 12 Given other biological advantages of neoadjuvant hormonal therapy 13, 14 is a reasonable approach in the majority of patients.
Using pre-treatment PSA measures as a surrogate of tumor cell burden at the time of presentation, it has been recently shown that the tumor cell burden has declined over the past decade. 15 Since the tumor control probability in general 11 depends upon tumor cell burden, the optimal dose of radiotherapy for PC needs to be carefully considered and determined. It is important to note that age appears to be a factor influencing toxicity, with older patients experiencing a higher percentage of toxicity in our data. Given the questionable benefit of treatment in elderly patients with early-stage, low-grade PC, decisions regarding treatment and RT dose in these men should be made very cautiously.
Our results, in terms of race and hospital of patient encounter, need to be interpreted cautiously. Because of referral patterns, the populations in the two hospitals differed in terms of racial and socioeconomic profile. To some extent, toxicity grading depends upon reporting of symptoms by patients. Whether patients of different socioeconomic status may differ in reporting their toxicities is not known, but likely. Future quality of life studies carefully documenting patients' self-reported symptoms will be able to determine whether such differences do exist.
In conclusion, our study shows that delivering conventional doses using conformal techniques leads to very minimal high-grade toxicity with a relatively long followup. However, even within a narrow dose range and fraction size used, differences do emerge suggesting higher incidence of toxicity with higher RT doses. This should lead one to be cautious before accepting higher RT doses as standard of care without sufficient follow-up. In addition, with the overall decline in tumor cell burden in recent years, the optimal dose for long-tem cure vs acceptable morbidity needs to be determined. Whether there needs to be a 'titration' of doses dependent upon a patient's age also needs to be studied carefully in the future.
